Stock VYGR VOYAGER THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Voyager Therapeutics, Inc.

Equities

VYGR

US92915B1061

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
7.55 USD -2.45% Intraday chart for Voyager Therapeutics, Inc. -14.01% -10.55%
Apr. 02 Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer CI
Apr. 02 Voyager Therapeutics, Inc. Announces CFO Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS
AQ
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
AQ
Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer
CI
Voyager Therapeutics, Inc. Announces CFO Changes
CI
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Guggenheim Initiates Voyager Therapeutics With Buy Rating, $22 Price Target
MT
H.C. Wainwright Initiates Coverage on Voyager Therapeutics With Buy Rating, $30 Price Target
MT
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) added to S&P Biotechnology Select Industry Index
CI
Voyager Therapeutics Appoints Toby Ferguson as Chief Medical Officer
MT
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
AQ
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024
CI
Citigroup Starts Voyager Therapeutics With Buy Rating, $16 Price Target
MT
Voyager Therapeutics: Q4 Earnings Snapshot
AQ
Transcript : Voyager Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
AQ
Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Voyager Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
AQ
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VYGR Stock
  4. News Voyager Therapeutics, Inc.